Clinical Trial Update: Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants [Phase 1]

View source ↗

Summary

A Phase 1 single-dose study of BMN 349 in adults with Alpha-1 antitrypsin deficiency is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• BMN 349

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 1 | Status: RECRUITING